The Administrative Core will provide overall leadership and coordination for the Consortium. Through its specimen repository and database management functions, it will ensure that there is a coordinated and efficient utilization of non-human primate samples derived from projects 1, 2 and 3. It will be responsible for collecting, storing and analyzing samples from the individual Research Programs and Cores within the Consortium, and will provide statistical support for data analysis, in order to ensure that effective and functional collaborative science results. The Administrative Core will maintain budgets and oversee any rebudgeting that may be needed to meet Consortium goals. The Core, in conjunction with the individual investigators and an external advisory committee, will ensure that established research milestones are met. It will organize monthly investigator meetings and teleconferences to ensure that regular opportunities for communication between the scientific components ofthe Consortium are established. It will organize the production and procurement of DNA and MVA vaccine components, as well as coordinate SIV peptide acquisition from the NIH AIDS Repository for individual research projects and cores. The Core will provide logistical support for timely sharing of data internally and externally through publications and presentations according to the Data Sharing Plan, and manage intellectual filings and MTAs as well as co-ordinate the distribution of unique resources under appropriate MTAs. Overall, the Administrative Core will provide the """"""""glue"""""""" to ensure that the Consortium funcfions as a highly collaborafive, interactive and effectively managed research program.
The Administrative Core will provide critical management functions for effective and successful pursuit ofthe research proposed in this Consortium application. Centralized management of samples and data, will facilitate efficient and collaborative use of unique samples and resources. Regular investigator meetings and teleconferences, will ensure communication between investigators, and allow timely publication of results.
|Kasturi, Sudhir Pai; Kozlowski, Pamela A; Nakaya, Helder I et al. (2017) Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5? Restrictive Macaques. J Virol 91:|
|Chamcha, Venkateswarlu; Kannanganat, Sunil; Gangadhara, Sailaja et al. (2016) Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine. Open Forum Infect Dis 3:ofw034|
|Cartwright, Emily K; Spicer, Lori; Smith, S Abigail et al. (2016) CD8(+) Lymphocytes Are Required for Maintaining Viral Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral Therapy. Immunity 45:656-668|
|Yu, Cuiling; Liu, Yanling; Chan, Justin Tze Ho et al. (2016) Identification of human plasma cells with a lamprey monoclonal antibody. JCI Insight 1:|
|Havenar-Daughton, Colin; Reiss, Samantha M; Carnathan, Diane G et al. (2016) Cytokine-Independent Detection of Antigen-Specific Germinal Center T Follicular Helper Cells in Immunized Nonhuman Primates Using a Live Cell Activation-Induced Marker Technique. J Immunol 197:994-1002|
|Kannanganat, Sunil; Wyatt, Linda S; Gangadhara, Sailaja et al. (2016) High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5?-Restrictive Macaques. J Immunol 197:3586-3596|
|Locci, Michela; Wu, Jennifer E; Arumemi, Fortuna et al. (2016) Activin A programs the differentiation of human TFH cells. Nat Immunol 17:976-84|
|Smith, S Abigail; Kilgore, Katie M; Kasturi, Sudhir Pai et al. (2016) Signatures in Simian Immunodeficiency Virus SIVsmE660 Envelope gp120 Are Associated with Mucosal Transmission but Not Vaccination Breakthrough in Rhesus Macaques. J Virol 90:1880-7|
|Cho, Alice; Wrammert, Jens (2016) Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine. Curr Opin Virol 17:110-5|
|Santangelo, Philip J; Rogers, Kenneth A; Zurla, Chiara et al. (2015) Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques. Nat Methods 12:427-32|
Showing the most recent 10 out of 51 publications